Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 2004

View Archived Issues

Curis licenses Hedgehog proteins and agonists for neurological disorders to Wyeth

FTC closes review of Genzyme's acquisition of Novazyme

KV Pharmaceutical enters into agreement with Glenmark

Protein Design Labs initiates partnership for optimized antibodies

Provid Pharmaceuticals and Suntory to develop multiple sclerosis drug candidates

Natural small molecule apoptotic inducer identified

NC-381 arrests lung tumor growth

AML apoptosis induction by novel retinoid analogue

Lysosomal acid lipase reported to reduce atherosclerotic plaque formation

IM-491 and rheumatoid arthritis therapy

Two series of 5-HT6 receptor ligands newly developed at Wyeth

Italian researchers describe new camptothecin analogues and their use

New V-ATPase inhibitors and their use as apoptosis inducers in EGFR-overexpressing cells

Novel CXCR3 antagonists under study at GSK

Santen and Asahi Glass claim new prostaglandin analogues for glaucoma and other ocular disorders

New analgesic sodium channel blockers covered by Merck patent

Euroceltique researchers present new opioid analgesics

Novel antidiabetic agents discovered by Bayer researchers

D-Pharm reacquires rights to epilepsy drug DP-VPA

Xcyte Therapies and Fresenius enter HIV gene therapy collaboration

MPC-6827 causes pancreatic tumor regression in preclinical studies

FDA approval for cytarabine aNDA

Rebetol launched for pediatric use

Guilford launches marketing efforts for Aggrastat, plans PCI registration study

Orphan drug designation sought for Virucort-50

ABX-EGF enters pivotal trial for colorectal cancer

Enbrel receives E.U. approval for treatment of ankylosing spondylitis

ViroPharma restructures operations

Large Scale Biology's alpha-galactosidase A shows potential for Fabry's disease

Triapine enters NCI-sponsored clinical trials

ProAlgaZyme may decrease risk of stroke or heart attack

Abciximab and clopidogrel in elective PCI

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...